Versions Compared

Old Version 15

changes.mady.by.user Daryl

Saved on

compared with

New Version 16

changes.mady.by.user Daryl

Saved on

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.

Two Shot Same Day Exception Rules for COVID-19

For COVID-19 The shots administered:

...

  • NOT apply because absolute minimum intervals between dose 1 and dose 2 = 0 days (before 10/25/2021) in both the Pfizer COVID-19 2-dose

...

  • series and Moderna COVID-19 2-dose

...

...

  • apply because absolute minimum intervals between dose 1 and dose 2 > 0 days (on or after 10/25/2021) in both the Pfizer COVID-19 2-dose series and Moderna COVID-19 2-dose series. 


Panel
borderColor#ccc
bgColor#D8D8D8
titleBGColor#D0D0D0
borderStylesolid
titleTable of Contents
Table of Contents

...

Panel
borderColor#CCFFFF
bgColor#CCFFFF
titleBGColor#99FFFF
borderStylesolid

Anchor
RecommendCVXorGroupLevel
RecommendCVXorGroupLevel
Rules for Recommending at the CVX Code vs. Vaccine Group Level 

  • If the patient has no shots on record, 
    • and is < 5 years old, recommend CVX 218 at 5 years old.
    • and is > = 5 years old and < 12 years old, recommend CVX 218 at today's date. 
    • and is > = 12 years old and < 18 years old, recommend CVX 208 at  recommend at the vaccine group level at today's date. 
    • and is > = 18 years old, recommend at the vaccine group level at today's date. 
  • If the patient has shots on recordrecord and the series is not complete,
    • and is < 5 years old, recommend CVX 218 at 5 years old.
    • and is > = 5 years old and < 12 years old (or will be < 12 years old at the recommended due date), recommend CVX 218 for the next target dose.
    • and is > = 12 years old (or will be >= 12 years old at the recommended due date) and < 18 years old,  recommend CVX 208 recommend at the vaccine group level for the next target dose. 
    • and is > = 18 years old and is in the following series:
      • Pfizer COVID-19 2-dose Series, recommend CVX 208 recommend at the vaccine group level for the next target dose.
      • Moderna COVID-19 2-dose Series, recommend CVX 207 recommend at the vaccine group level for the next target dose.
      • Janssen COVID-19 1-dose Series, recommend CVX 212 recommend at the vaccine group level for the next target dose. 

Series Completion Special Rule

  • Once a patient completes:
    • the Pfizer COVID-19 (5-17) 2-dose series, Moderna COVID-19 2-dose series, 
      • and is < 18 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK. 
      • and receives an additional dose1, the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
      the Pfizer COVID-19 2-dose series with CVX 208 as Dose 1 and Dose 2,and is >= 65 years old, recommend a booster dose of Pfizer (CVX 208) at Dose 2 +  a COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, 
      • recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (6 months) or at recommended age (18 years), whichever date is later, along with recommendation reason codes BOOSTERcode BOOSTER_DOSE. (new recommendation reason code)and is >= 18 years and < 65 years old, the recommendation is Conditional   
      • and receives an additional dose1, the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
      • and receives an additional dose1 or a booster dose2, the Recommendation is Not Recommended and the reason code is COMPLETE.
    • the Pfizer COVID-19 2-dose series where not all doses administered were CVX 208 or the Moderna COVID-19 2-dose series, the Recommendation (5-17) 2-dose series, 
      • and is >= 16 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (6 months) or at recommended age (18 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE
      • and is < 16 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK. 
      • and receives an additional dose1, the Recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
      • and receives a booster dose2, the Recommendation is Not Recommended and the reason code is COMPLETE.
    • either the 1) Janssen COVID-19 1-dose series, 2) COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a 3) COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, the Recommendation is Not Recommended/ COMPLETE 
      • and is >= 18 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), along with recommendation reason code BOOSTER_DOSE.  
      • and is < 18 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK. 
      • and receives a booster dose2, the Recommendation is Not Recommended and the reason code is COMPLETE.

Rules for an Additional Dose1

  • If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 2-dose series or , Moderna COVID-19 2-dose series and series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives an additional shot of CVX 208, CVX 217, CVX 207, or CVX 213:
    • at < 28 days - 4 days after series completion, then evaluate the shot as Validas Valid/  SUPPLEMENTALSUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum age and/or minimum intervalinterval of 28 days required for an Additional Dose for immunocompromised patients or the minimum interval of 6 months required for a Booster Dose."
    • at >= 28 days - 4 days and < 6 months after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 6 months required for a Booster Dose."
    If a patient is >=12 years
    • at >= 6 months after series completion, then evaluate the shot as Valid. 
  • If a patient is >= 12 years old, completes a COVID-19 vaccine series via the Pfizer COVID-19 (5-17) 2-dose series and receives an additional shot of CVX 218, CVX 208, CVX 217, CVX 207, or CVX 213:
    • at < 28 days
- 4 days
    • after series completion, then evaluate the shot
as Invalid
    • as Valid/
BELOW_MINIMUM_INTERVAL. 
  • at >= 28 days - 4 days, then evaluate the shot as Valid. 

    • Rules for Booster Dose2

    If a patient completes a COVID-19 vaccine series via the Pfizer 2-dose series (with CVX 208 only) and a booster dose2 of CVX 208, at < 28 days - 4 days after
      • SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 28 days required for an Additional Dose for immunocompromised patients or the minimum interval of 6 months required for a Booster Dose."
      • at >= 28 days and < 6 months after series completion, then evaluate the shot
    as Valid
      • as Valid/
     SUPPLEMENTAL
      • SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum
    age and/or minimum interval.
      • interval of 6 months required for a Booster Dose."
      • at >=
    28 days - 4 days after
      • 6 months after series completion, then evaluate the shot as Valid.
  • If a patient completes a COVID-19 vaccine series via the Janssen 1-dose series and a booster dose of CVX 212, CVX 208, CVX 207, or CVX 213, then evaluate the booster dose as Valid.

    • Rules for Extra Shots After Additional Dose1and/or Booster Dose2

    • For patients that completed the Pfizer COVID-19 Child (5-17) 2-dose Series, 
      • is < 12 years old, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
      • is > = 12 years old and received an Additional Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
    Panel
    borderColor#FDF5E6
    bgColor#FDF5E6
    titleBGColor#FAEBD7
    borderStylesolid

    Notes

    • 1Additional Dose - Defined by ACIP to be a dose administered when the immune response to a standard primary vaccine series is likely not to be protective. 
    • 2Booster Dose - Defined by ACIP to be a dose administered to restore protection after the effectiveness of protection from the primary series has declined. 

    COVID-19 Vaccines

    ...

    CVX Code

    ...

    Name

    ...

    Moderna COVID-19 Vaccine

    ...

    208

    ...

    Pfizer COVID-19 Vaccine

    ...

    500

    ...

    COVID-19 Non-US Vaccine, Product Unknown 

    ...

    501

    ...

      •  

    Rules for Booster Dose2

    Any of the FDA-Approved COVID-19 vaccines (except CVX 218) can be used for booster vaccination, regardless of the vaccine product used for primary vaccination. When a heterologous or “mix and match” booster dose is administered, the eligible population and dosing intervals are those of the vaccine used for primary vaccination.

    Recommendation Rules for Booster Dose

    • Recommend at the Vaccine Group Level (along with recommendation reason code BOOSTER_DOSE)
    • Recommended Age = 18 years
    • Minimum Age = 16 years
    • Recommended Interval
      • After completion of Pfizer 2-dose series, Moderna 2-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine = 6 months
      • After completion of Janssen 1-dose series = 8 weeks

    Evaluation Rules for Booster Dose

    • Any of the FDA-Approved COVID-19 vaccines (except CVX 218) are allowed for the Booster Dose.
    • Absolute Minimum Interval = 0 days
    • If a patient completes a COVID-19 vaccine series via the Pfizer 2-dose series, Moderna 2-dose series, Pfizer COVID-19 Child (5-17) 2-dose series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives a Booster Dose2 of CVX 208, CVX 217, CVX 207, CVX 212, or CVX 213: 
      • at < 28 days after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 28 days required for an Additional Dose for immunocompromised patients or the minimum interval of 6 months required for a Booster Dose."
      • at >= 28 days and < 6 months after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 6 months required for a Booster Dose."
      • at >= 6 months after series completion, then evaluate the shot as Valid. 
    • If a patient completes a COVID-19 vaccine series via the Janssen 1-dose series and receives a Booster Dose2 of CVX 208, CVX 217, CVX 207, CVX 212, or CVX 213:
      • at < 8 weeks after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks required for a Booster Dose."
      • at >= 8 weeks after series completion, then evaluate the shot as Valid.

    Rules for Extra Shots After Additional Dose1and/or Booster Dose2

    • For patients that completed the Pfizer COVID-19 2-dose series, Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE. 
    • For patients that completed the Pfizer COVID-19 Child (5-17) 2-dose Series, 
      • is < 12 years old, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
      • is > = 12 years old and < 16 years old and received an Additional Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
      • is > = 16 years old and received an Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE. 
    • For patients that completed the Moderna COVID-19 2-dose series, Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE. 
    • For patients that completed Janssen COVID-19 1-dose series and Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE. 
    • For patients that completed either the 1) COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a 2) COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, Additional Dose and/or Booster Dose, any shots administered after the primary series is evaluated as Accepted/EXTRA_DOSE.


    Panel
    borderColor#FDF5E6
    bgColor#FDF5E6
    titleBGColor#FAEBD7
    borderStylesolid

    Notes

    • 1Additional Dose - Defined by ACIP to be a dose administered when the immune response to a standard primary vaccine series is likely not to be protective. 
    • 2Booster Dose - Defined by ACIP to be a dose administered to restore protection after the effectiveness of protection from the primary series has declined. 

    COVID-19 Vaccines

    CVX Code

    Name

    		Absolute Minimum AgeAbsolute Maximum AgeCounts towards U.S. Vaccination
    207

    Moderna COVID-19 Vaccine

    		0 days
    		Yes

    208

    Pfizer COVID-19 Vaccine

    		0 days
    		Yes
    210AstraZeneca COVID-19 Vaccine0 days
    		Yes, only if all recommended doses are administered.
    211Novavax COVID-19 Vaccine0 days
    		Yes, only if all recommended doses are administered.
    212Janssen COVID-19 Vaccine0 days
    		Yes
    213SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED0 days
    		Yes
    217Pfizer COVID-19 Vaccine0 days
    		Yes
    218Pfizer COVID-19 Vaccine (5-11 years)0 days18 years minus 1 dayYes

    500

    COVID-19 Non-US Vaccine, Product Unknown 



    		No

    501

    COVID-19 IV Non-US Vaccine (QAZCOVID-IN)



    		No

    502

    COVID-19 IV Non-US Vaccine (COVAXIN)

    		0 days
    		Yes, only if all recommended doses are administered.

    503

    COVID-19 LAV Non-US Vaccine (COVIVAC)



    		No

    504

    COVID-19 VVnr Non-US Vaccine (Sputnik Light)



    		No

    505

    COVID-19 VVnr Non-US Vaccine (Sputnik V)



    		No

    506

    COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology)



    		No

    507

    COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences)



    		No

    508

    COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)



    		No

    509

    COVID-19 PS Non-US Vaccine (EpiVacCorona)



    		No

    510

    COVID-19 IV Non-US Vaccine (BIBP, Sinopharm)

    		0 days
    		Yes, only if all recommended doses are administered.

    511

    COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac)

    		0 days
    		Yes, only if all recommended doses are administered.

    ...

    Panel
    borderColor#CCFFFF
    bgColor#CCFFFF
    titleBGColor#99FFFF
    borderStylesolid

    CVX Code Specific Rules

    CVX Code Absolute Minimum Age

    • If one of the CVX codes in the table above is administered below the absolute minimum age for that CVX code, then the Evaluation is Invalid and the reason code is BELOW_MINIMUM_AGE_VACCINE

    CVX Code Absolute Maximum Age

    • If one of the CVX codes in the table above is administered above the absolute maximum age for that CVX code, then the Evaluation is Invalid and the reason code is ABOVE_MAXIMUM_AGE_VACCINE.

    Rule for CVX 213

    • If the patient receives CVX 213 for:
      • Target Dose 1, evaluate the shot as Valid.Recommend Target Dose 2 at Vaccine Group levelas Valid.
        • Recommended interval = 28 days
        • Recommended age = 5 years
      • Target Dose 2, evaluate the shot as Valid. 
      • If the patient receives CVX 213 for Target Dose 1 and CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,  
        • evaluate Target Dose 2 (CVX 212) as Valid.
        • evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.
      • If the patient has CVX 213 on their patient record AND receives all recommended doses of a 1) COVID-19 vaccine not authorized by the FDA, but authorized by the WHO or 2) COVID-19 vaccine not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, then 
        • evaluate CVX 213 shots given before series completion as Accepted/ VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.
          • Example Scenario #1 - Patient receives the following shots (listed in order): CVX 213, CVX 210 (AstraZeneca), CVX 210 (AstraZeneca) 
            • CVX 213 shot is evaluated as Accepted/ VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN
            • Both CVX 210 shots are evaluated as Valid (series is complete via AstraZeneca 2-dose series)
          • Example Scenario #2 - Patient receives the following shots (listed in order): CVX 210 (AstraZeneca), CVX 213, CVX 210 (AstraZeneca) 
          • Example Scenario #1 - Patient receives the following shots (listed in order): CVX 210 (AstraZeneca), CVX 210 (AstraZeneca), CVX 213 
            • CVX 213 shot is evaluated as Accepted/ VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN
            • Both CVX 210 shots are evaluated as Valid (series is complete via AstraZeneca 2-dose series)
          evaluate CVX 213 shots given after series completion as Accepted/ EXTRA_DOSE. 
            • _GIVEN
            • Both CVX 210 shots are evaluated as Valid (series is complete via AstraZeneca 2-dose series)CVX 213 is evaluated as Accepted/ EXTRA_DOSE
        • evaluate CVX 213 shots given after series completion as Valid (if eligible for an Additional Dose or Booster Dose) or Accepted/ EXTRA_DOSE (if NOT eligible for an Additional Dose or Booster Dose). 

    Rules for COVID-19 Vaccines Not Authorized by FDA2

    The following set of rules apply to 1) COVID-19 Vaccines Not Authorized by FDA, but Authorized by WHO and, 2) COVID-19 Vaccines Not Authorized by FDA or WHO, but is an Active COVID-19 Vaccine Candidate as part of a U.S.-based Clinical Trial of a COVID-19 Vaccine. 

    • The list of COVID-19 Vaccines Not Authorized by the FDA, but Authorized by the WHO are:

      • CVX 210 - AstraZeneca COVID-19 Vaccine

      • CVX 510 - BIBP, Sinopharm COVID-19 Vaccine
      • CVX 511 - CoronaVac, Sinovac
      • CVX 502 - COVAXIN

    • The list of COVID-19 Vaccines Not Authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine are:

      • CVX 211- Novavax COVID-19 Vaccine

    • If the patient has received all recommended doses of the COVID-19 vaccine, then: 
      • Evaluate the shots as Valid; (Absolute Minimum Interval = 0 days; Absolute Minimum Age = 0 days)
      • No additional doses Recommend a booster dose of COVID-19 vaccine are needed; Recommendation: Not Recommended/ COMPLETE_HIGH_RISK.(at vaccine group level) at recommended interval (6 months), along with recommendation reason code BOOSTER_DOSE.  
    • If the patient has received one or more doses, but has not received all the recommended doses for that COVID-19 vaccine, then:
      • Evaluate the shot(s) as Accepted/ VACCINE_NOT_APPROVED_IN_US. 
      • Recommendation:
        • If one of the above listed COVID-19 vaccine is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days) or at 5 years old, whichever date is later. 
          • Example #1: Patient has 1 shot of CVX 210 (AstraZeneca) on record.
            • Evaluate CVX 210 as Accepted/ VACCINE_NOT_APPROVED_IN_US.
            • Recommend COVID-19 at the vaccine group level for Target Dose 1 at CVX 210 + recommended interval (28 days). 
          • Example #2: Patient has 1 shot of CVX 208 (Pfizer), then 1 shot of CVX 210 (AstraZeneca) on record. 
            • Evaluate CVX 208 as Valid and CVX 210 as Accepted/ VACCINE_NOT_APPROVED_IN_US.
            • Recommend COVID-19 at the vaccine group level for Target Dose 2 at CVX 210 + recommended interval (28 days). 
          • If one of the above listed COVID-19 vaccine is NOT the last COVID-19 shot administered, recommend based on the series that applies for the last COVID-19 shot administered.
            • Example: If CVX 208 (Pfizer) is given after CVX 210 (AstraZeneca), then recommend based on the Pfizer COVID-19 2-dose Series.


    The following set of rules apply to COVID-19 Vaccines Not Authorized by FDA or WHO. 

    • The list of COVID-19 Vaccines Not Authorized by the FDA or WHO are:

      • CVX 500 - COVID-19 Non-US Vaccine, Product Unknown 
      • CVX 501 - COVID-19 IV Non-US Vaccine (QAZCOVID-IN)
      • CVX 503 - COVID-19 LAV Non-US Vaccine (COVIVAC) 
      • CVX 504 - COVID-19 VVnr Non-US Vaccine (Sputnik Light) 
      • CVX 505 - COVID-19 VVnr Non-US Vaccine (Sputnik V)
      • CVX 506 - COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology)
      • CVX 507 - COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences)
      • CVX 508 - COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention)
      • CVX 509 - COVID-19 PS Non-US Vaccine (EpiVacCorona)
    • If the patient has received a COVID-19 vaccine not authorized by the FDA or WHO for all or some or the recommended doses of the COVID-19 vaccine, then: 
      • Evaluate the shot(s) as Invalid/ VACCINE_NOT_APPROVED_IN_US_OR_BY_WHO. 
      • Recommendation:
        • If one of the above listed COVID-19 vaccine is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days) or at 5 years old, whichever date is later.  
          • Example #1: Patient has 1 shot of CVX 501 on record.
            • Evaluate CVX 501 as Invalid/ VACCINE_NOT_APPROVED_IN_US_OR_BY_WHO.
            • Recommend COVID-19 at the vaccine group level for Target Dose 1 at CVX 501 + recommended interval (28 days). 
          • Example #2: Patient has 1 shot of CVX 208 (Pfizer), then 1 shot of CVX 501 on record. 
            • Evaluate CVX 208 as Valid and CVX 501 as Invalid/ VACCINE_NOT_APPROVED_IN_US_OR_BY_WHO.
            • Recommend COVID-19 at the vaccine group level for Target Dose 2 at CVX 501 + recommended interval (28 days). 
        • If one of the above listed COVID-19 vaccine is NOT the last COVID-19 shot administered, recommend based on the series that applies for the last COVID-19 shot administered.
          • Example: If CVX 208 (Pfizer) is given after CVX 501, then recommend based on the Pfizer COVID-19 2-dose Series.

    ...

    Panel
    borderColor#CCFFFF
    bgColor#CCFFFF
    titleBGColor#99FFFF
    borderStylesolid

    Series Name

    • Pfizer COVID-19 Child (5-17) 2-dose Series
    • Pfizer COVID-19 2-dose Series
    • Moderna COVID-19 2-dose Series
    • Janssen COVID-19 1-dose Series

    Series Selection Rules

    There are four series for this vaccine group: the Pfizer COVID-19 Child (5-17) 2-dose Series, Pfizer COVID-19 2-dose series, Moderna COVID-19 2-dose series, and Janssen COVID-19 1-dose series. The rules for determining which series applies are:

    • If patient is < 18 years , and
      • dose 1 is CVX
      218 or CVX 208, then the Pfizer
      • 212, then the Janssen COVID-19 1-dose series applies.
      • Otherwise, the Pfizer COVID-19 Child (5-17) 2-dose series applies. 
    • If patient If the patient is >= 18 years and dose 1 is CVX 208and
      • dose 1 is CVX 208 or CVX 217, then the Pfizer COVID-19 2-dose series applies. 
      If
      • dose 1 is CVX 207, then the Moderna COVID-19 2-dose series applies. 
      If
      • dose 1 is CVX 212, then the Janssen COVID-19 1-dose series applies. 
      If
      • dose 1 is CVX 213, reference the "Rule for CVX 213
      " rules above. If no shots are on patient record, reference the "Rules for Recommending at the CVX Code vs. Vaccine Group Level
      • " rules above. 

    Immunization Series: Pfizer COVID-19 Child (5-17) 2-dose Series  

    ...

    Dose

    Series Name

    Absolute Minimum
     Age

    		Minimum Age

    Routine
    Age

    Latest Recommended Age (less than)

    		Valid CVX Code(s) per Dose for this SeriesInvalid CVX Code(s) per Dose for this Series

    1

    Pfizer COVID-19 Child (5-17) 2-dose Series


    0 days

    5 years


    5 years

    		N/A

    218, 208, 217, 207, 213

    N/A

    2

    Pfizer COVID-19 Child (5-17) 2-dose Series

    0 days

    5 years


    5 years


    		N/A218, 208, 217, 207 207, 213

    N/A


    Panel
    borderColor#CCFFFF
    bgColor#CCFFFF
    titleBGColor#99FFFF
    borderStylesolid

    Series Special Rules

    • If the patient receives a shot at < 5 years old, evaluate the shot as Valid, with reason code SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum age."

    Rule for CVX 212 (Janssen COVID-19 Vaccine)

    • If CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,  
      • evaluate Target Dose 2 (CVX 212) as Valid.
      • evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.

    Immunization Series: Pfizer COVID-19 2-dose Series

    The Pfizer COVID-19 2-dose series is complete after 2 doses. 

    Vaccine Dose Parameters - Minimum and Routine Ages 

    ...

    Dose

    ...

    Series Name

    ...

    Absolute Minimum
     Age

    ...

    Routine
    Age

    ...

    1

    ...

    Pfizer COVID-19 2-dose Series

    ...

    18 years

    ...

    2

    ...

    Pfizer COVID-19 2-dose Series

    ...

    18 years

    ...

    18 years

    ...

    Vaccine Dose Parameters - Minimum and Recommended Intervals

    ...

    Doses

    ...

    Series Name

    ...

    Absolute Minimum Interval

    ...

    Minimum Recommended Interval

    ...

    Vaccine Dose Parameters - Minimum and Recommended Intervals

    ...

    Doses

    ...

    Series Name

    ...

    Absolute Minimum Interval

    ...

    Recommended Interval

    ...

    Dose 1 to 2

    ...

    Pfizer COVID-19 Child (5-17) 2-dose Series

    ...

    17 days 

    ...

    21 days

    ...

    - Minimum and Recommended Intervals

    Doses

    Series Name

    Absolute Minimum Interval

    		Minimum Interval

    Recommended Interval

    		Latest Recommended Interval (less than)

    Dose 1 to 2

    Pfizer COVID-19 Child (5-17) 2-dose Series

    17 days 

    		21 days

    21 days

    		N/A


    Panel
    borderColor#CCFFFF
    bgColor#CCFFFF
    titleBGColor#99FFFF
    borderStylesolid

    Series Special Rules

    • If the patient receives a shot at < 5 years old, evaluate the shot as Valid, with reason code SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum age."

    Rule for CVX 212 (Janssen COVID-19 Vaccine)

    • If CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,  
      • evaluate Target Dose 2 (CVX 212) as Valid.
      • evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.

    Rule for CVX 207 (Moderna COVID-19 Vaccine) Administered < 18 years old

    • If the patient is administered Moderna COVID-19 vaccine (CVX 207):
      • between ages >= 5 years and < 12 years 
        • for Target Dose 1, evaluate the shot as Valid. Recommend CVX 218 for Target Dose 2 at Dose 1 + recommended interval (28 days).
        • for Target Dose 2, evaluate the shot as Valid. Recommend Conditional/ COMPLETE_HIGH_RISK.
      • between ages >= 12 years and < 18 years 
        • for Target Dose 1, evaluate the shot as Valid. Recommend at the vaccine group level for Target Dose 2 at Dose 1 + recommended interval (28 days).
        • for Target Dose 2, evaluate the shot as Valid. Recommend Conditional/ COMPLETE_HIGH_RISK. 

    Immunization Series: Pfizer COVID-19 2-dose Series

    The Pfizer COVID-19 2-dose series is complete after 2 doses. 

    Vaccine Dose Parameters - Minimum and Routine Ages 

    Dose

    Series Name

    Absolute Minimum
     Age

    		Minimum Age

    Routine
    Age

    		Latest Recommended Age (less than)Valid CVX Code(s) per Dose for this SeriesInvalid CVX Code(s) per Dose for this Series

    1

    Pfizer COVID-19 2-dose Series

    0 days

    21 days21 days

    N/A

    Vaccine Dose Parameters - Minimum and Recommended Intervals

    Doses

    Series Name

    Absolute Minimum Interval

    Minimum Interval

    Recommended Interval

    Latest Recommended Interval (less than)Dose 1 to 2

    18 years

    		18 years18 yearsN/A
    Panel
    borderColor#CCFFFF
    bgColor#CCFFFF
    titleBGColor#99FFFF
    borderStylesolid

    Series Special Rules

    • If the patient receives a shot at < 21 days - 4 days interval between dose 1 and 2, evaluate the shot as Valid, with reason code SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum age and/or minimum interval."

    Rule for CVX 218 (Pfizer COVID-19 Vaccine (5-11))

    • If the patient is >= 18 years old and administered Pfizer COVID-19 Vaccine (CVX 218):
      • as Target Dose 1 or Target Dose 2, evaluate as Invalid/ ABOVE_MAXIMUM_AGE_VACCINE. 

    Rule for CVX 212 (Janssen COVID-19 Vaccine)

    • If CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,  
      • evaluate Target Dose 2 (CVX 212) as Valid.
      • evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.

    Immunization Series: Moderna COVID-19 2-dose series

    The Moderna COVID-19 2-dose series is complete after 2 doses. 

    Vaccine Dose Parameters - Minimum and Routine Ages 

    ...

    Dose

    ...

    Series Name

    ...

    Absolute Minimum
     Age

    ...

    Routine
    Age

    ...

    Latest Recommended Age (less than)

    ...

    1

    ...

    Moderna COVID-19 2-dose Series

    ...

    0 days

    ...

    18 years

    ...

    N/A

    ...

    2

    ...

    Moderna COVID-19 2-dose Series

    ...

    208, 217, 213

    		N/A

    2

    Pfizer COVID-19 2-dose Series

    18 years

    		18 years

    18 years

    		N/A208, 217, 207, 213N/A

    Vaccine Dose Parameters - Minimum and Recommended Intervals

    Doses

    Series Name

    Absolute Minimum Interval

    		Minimum Interval

    Minimum Recommended Interval

    		Latest Recommended Interval (less than)

    Dose 1 to 2

    Pfizer COVID-19 2-dose Series

    0 days if dose 2 administered < 10/25/2021

    17 days if dose 2 administered >= 10/25/2021

    		21 days

    21 days

    		N/A


    Panel
    borderColor#CCFFFF
    bgColor#CCFFFF
    titleBGColor#99FFFF
    borderStylesolid

    Series Special Rules

    Rule for CVX 218 (Pfizer COVID-19 Vaccine (5-11))

    • If the patient is >= 18 years old and administered Pfizer COVID-19 Vaccine (CVX 218):
      • as Target Dose 1 or Target Dose 2, evaluate as Invalid/ ABOVE_MAXIMUM_AGE_VACCINE. 

    Rule for CVX 212 (Janssen COVID-19 Vaccine)

    • If CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,  
      • evaluate Target Dose 2 (CVX 212) as Valid.
      • evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.

    Immunization Series: Moderna COVID-19 2-dose series

    The Moderna COVID-19 2-dose series is complete after 2 doses. 

    Vaccine Dose Parameters - Minimum and Routine Ages 

    ...

    • for Target Dose 1, evaluate the shot as Valid. Recommend CVX 218 for Target Dose 2 at Dose 1 + recommended interval (28 days).
    • for Target Dose 2, evaluate the shot as Valid. Recommend Conditional/ COMPLETE_HIGH_RISK.

    ...

    Dose

    Series Name

    Absolute Minimum
     Age

    		Minimum Age

    Routine
    Age

    Latest Recommended Age (less than)

    		Valid CVX Code(s) per Dose for this SeriesInvalid CVX Code(s) per Dose for this Series

    1

    Moderna COVID-19 2-dose Series

    0 days

    28 days28 days

    18 years - 4 days 

    		18 years

    18 years

    		N/A

    ...

    borderColor#CCFFFF
    bgColor#CCFFFF
    titleBGColor#99FFFF
    borderStylesolid

    Series Special Rules

    • If the patient receives a shot at < 18 years - 4 days of age and/or < 28 days - 4 days interval between dose 1 and 2, evaluate the shot as Valid, with reason code SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum age and/or minimum interval."

    Rule for CVX 218 (Pfizer COVID-19 Vaccine (5-11))

    • If the patient is >= 18 years old and administered Pfizer COVID-19 Vaccine (CVX 218):
      • as Target Dose 1 or Target Dose 2, evaluate as Invalid/ ABOVE_MAXIMUM_AGE_VACCINE. 

    Rule for CVX 207 (Moderna COVID-19 Vaccine) Administered < 18 years old

    ...

    207, 213

    N/A


    2

    Moderna COVID-19 2-dose Series

    		18 years - 4 days 18 years18 yearsN/A207, 208, 217, 213

    N/A


    Vaccine Dose Parameters - Minimum and Recommended Intervals

    Doses

    Series Name

    Absolute Minimum Interval

    		Minimum Interval

    Recommended Interval

    		Latest Recommended Interval (less than)

    Dose 1 to 2

    Moderna COVID-19 2-dose Series

    0 days if dose 2 administer < 10/25/2021

    24 days if dose 2 administered >= 10/25/2021

    		28 days

    28 days

    		N/A


    Panel
    borderColor#CCFFFF
    bgColor#CCFFFF
    titleBGColor#99FFFF
    borderStylesolid

    Series Special Rules

    Rule for CVX 218 (Pfizer COVID-19 Vaccine (5-11))

    • If the patient is >= 18 years old and administered Pfizer COVID-19 Vaccine (CVX 218):
      • as Target Dose 1 or Target Dose 2, evaluate as Invalid/ ABOVE_MAXIMUM_AGE_VACCINE. 

    Rule for CVX 212 (Janssen COVID-19 Vaccine)

    • If CVX 212 (Janssen COVID-19 Vaccine) is reported for Target Dose 2, the Janssen COVID-19 1-dose Series applies and the series is complete. Therefore,  
      • evaluate Target Dose 2 (CVX 212) as Valid.
      • evaluate Target Dose 1 as Accepted and the reason code is VACCINE_NOT_COUNTED_BASED_ON_MOST_RECENT_VACCINE_GIVEN.

    ...